PRISM0CAL B22K0/0 7.14 G
SODIUM CHLORIDE : 7.14 G MAGNESIUM CHLORIDE : 3.05 G SODIUM BICARBONATE : 2.12 G · DIN 02441691 · VANTIVE ULC
Health Canada status: MARKETED
What is PRISM0CAL B22K0/0?
PRISM0CAL B22K0/0 7.14 G contains SODIUM CHLORIDE : 7.14 G MAGNESIUM CHLORIDE : 3.05 G SODIUM BICARBONATE : 2.12 G. It is listed in the Health Canada Drug Product Database under DIN 02441691, held by VANTIVE ULC, supplied as SOLUTION for INTRAVENOUS ; HAEMODIALYSIS administration. Health Canada currently lists it as marketed, status dated 19-Apr-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PRISM0CAL B22K0/0 used for?
Prism 0CAL B22K0/0 is indicated for: • treatment of acute renal failure as replacement solution in hemofiltration or hemodiafiltration and as dialysis solution in hemodialysis or hemodiafiltration in continuous renal replacement therapy (CRRT). • patients who have tendency to hyperkalaemia and/or hypercalcemia, • treatment in case of drug poisoning with dialyzable or filterable substances.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02441691 |
|---|---|
| Brand name | PRISM0CAL B22K0/0 |
| Generic / active ingredient | SODIUM CHLORIDE : 7.14 G MAGNESIUM CHLORIDE : 3.05 G SODIUM BICARBONATE : 2.12 G |
| Manufacturer | VANTIVE ULC |
| Strength | 7.14 G |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS ; HAEMODIALYSIS |
| Schedule | Ethical |
| ATC code | B05ZB HEMOFILTRATES |
| AHFS class | 08:12.16.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 19-Apr-2024 |
How is it stored and handled?
Store between 4°C and 30°C. Do not refrigerate. Protect from freezing.
How is it supplied?
2 x 5000 mL in a box
What can be used instead?
Other Canadian products sharing ATC code B05ZB HEMOFILTRATES. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| REGIOCIT | 5.03 G | SOLUTION | VANTIVE ULC | MARKETED | DIN 02496755 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.